Novel combinatorial approaches in disease subsets with multiple targets (i.e., NPM1- and FLT3-ITD mutated AML) may allow for lessened reliance on traditional cytotoxic agents that form the backbone of AML treatments. The gene discussed is FLT3; the disease is acute myeloid leukemia.